Evaluation of Hepatic Mitochondria and Hematological Parameters in Zidovudine-Treated B6C3F₁ Mice

Table 1

Levels of hematological parameters in B6C3F₁ mice.

AZT; dose; (mg/kg/d)

RBC count; (10^6/mm^3)

Hb content; (g/dL)

MCV; (μm^3)

MCH; (pg)

0-week

11-week

0-week

11-week

0-week

11-week

0-week

11-week

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

0

9.9; ±; 0.3

10.1; ±; 0.5

11.0^a; ±; 0.1

11.5; ±; 0.3

16.5; ±; 0.6

16.9; ±; 0.7

16.9; ±; 0.5

18.2; ±; 0.7

46.6; ±; 0.2

47.0; ±; 0.3

47.0; ±; 2.0

48.5; ±; 1.2

16.4; ±; 0.3

16.6; ±; 0.2

15.4; ±; 0.5

15.8^a; ±; 0.3

400

8.7; ±; 0.7

9.8; ±; 0.5

7.6; ±; 0.4

7.3^a; ±; 0.3

14.2; ±; 1.2

16.5; ±; 0.9

14.4; ±; 0.9

14.4; ±; 0.8

47.2; ±; 0.3

46.8; ±; 0.3

57.8^a; ±; 0.3

60.5^a,b; ±; 0.5

16.5; ±; 0.1

16.7; ±; 0.2

19.0^a; ±; 0.1

19.8^a,b; ±; 0.2

500

8.6; ±; 0.7

10.0; ±; 0.7

7.7; ±; 0.1

8.4^b; ±; 0.1

14.1; ±; 1.2

16.5; ±; 1.2

14.8; ±; 0.3

16.5^b; ±; 0.2

47.8; ±; 0.3

46.7; ±; 0.2

58.5^a; ±; 0.5

60.3^a,b; ±; 0.3

16.4; ±; 0.1

16.4; ±; 0.2

19.2^a; ±; 0.1

19.7^a,b; ±; 0.1

600

8.6; ±; 0.7

8.8; ±; 0.3

7.9; ±; 0.5

6.7^a; ±; 1.1

14.1; ±; 1.2

14.4; ±; 0.4

15.6; ±; 0.8

13.6; ±; 2.1

46.6; ±; 0.7

46.2; ±; 0.6

60.3^a; ±; 0.7

63.0^a; ±; 1.0

16.2; ±; 0.2

16.2; ±; 0.1

19.7^a; ±; 0.2

20.6^a; ±; 0.4

^aindicates a significant (𝑃<0.05) difference in hematological parameter at 11-week compared to 0-week for each sex.
^bindicates a significant (𝑃<0.05) sex-based difference in hematological parameter in female mice compared to male counterparts at 11-week. Values are presented as the mean ± SEM (𝑁=4–6). Also, a significant (𝑃<0.05) dose-related response was noted in the RBC count, Hb content, MCV, and MCH level in both sexes.